rubitecan has been researched along with Neoplasm Metastasis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guiney, P; Haney, LG; Lenaz, L; Miller, KD; Murry, DJ; Sledge, GW; Soule, SE; Sun, SL | 1 |
| Gilbert, BE; Huaringa, A; Knight, V; Loyer, E; Newman, RA; Verschraegen, CF; Walsh, G | 1 |
| Baron, B; Chollet, P; de Jonge, MJ; de Wit, R; Droz, JP; Fumoleau, P; Lacombe, D; Mettinger, K; Paz-Ares, L; van Oosterom, AT | 1 |
| Chedid, S; Cristofanilli, M; Esteva, F; Frye, DK; Hortobagyi, G; Ibrahim, N; Mettinger, KL; Rivera, E; Valero, V | 1 |
| Caponigro, F; Cartenì, G; Davis, WB; Droz, JP; Milano, A; Pollard, P | 1 |
| Bedikian, AY; Ellerhorst, JA; Eton, O; Papadopoulos, NE; Plager, C; Smith, TM | 1 |
| Adank, S; Beijnen, JH; Botma, HJ; Ganser, A; Herr, A; Rosing, H; Schöffski, P; Van den Brande, J; Vermorken, JB; Volk, J; Wanders, J | 1 |
7 trial(s) available for rubitecan and Neoplasm Metastasis
| Article | Year |
|---|---|
A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Camptothecin; Female; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis | 2004 |
Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Topoisomerase Inhibitors | 2004 |
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2004 |
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2006 |
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Skin Neoplasms; Treatment Outcome; Uveal Neoplasms | 2002 |
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Eating; Female; Humans; Male; Middle Aged; Neoplasm Metastasis | 2002 |